Relay Therapeutics, Inc. (RLAY) insider trading.
In Q3 2026, insiders at Relay Therapeutics, Inc. reported 16 non-derivative transactions on 14 Forms 3, 4 and 5: 0 open-market purchases and 14 sales worth $121.7M.
- Transactions
- 16
- Purchases (P)
- 0
- Sales (S)
- 14
- Net shares, P minus S
- -6,273,890
- Insiders
- 5
- Last filed
- 2026-09-09
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Patel Sanjiv | Director, Officer · President and CEO | 4 | 0 | 3 |
| Catinazzo Thomas | Officer · Chief Financial Officer | 4 | 0 | 4 |
| Rahmer Peter | Officer · See remarks | 4 | 0 | 3 |
| Bergstrom Donald A | Officer · President, R&D | 3 | 0 | 3 |
| SB INVESTMENT ADVISERS (UK) LTD / SVF Pauling (Cayman) Ltd / SOFTBANK VISION FUND (AIV M2) L.P. | TenPercentOwner | 1 | 0 | 1 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | Patel Sanjiv | S (D) | 48,199 | $18.94 | 519,500 | Form 4 |
| 2026-09-08 | Catinazzo Thomas | S (D) | 17,717 | $18.94 | 122,851 | Form 4 |
| 2026-09-08 | Bergstrom Donald A | S (D) | 8,530 | $18.97 | 399,130 | Form 4 |
| 2026-08-26 | Rahmer Peter | S (D) | 4,508 | $20.03 | 223,657 | Form 4 |
| 2026-08-25 | SB INVESTMENT ADVISERS (UK) LTD / SVF Pauling (Cayman) Ltd / SOFTBANK VISION FUND (AIV M2) L.P. | S (D) | 6,000,000 | $19.4 | 21,904,963 | Form 4 |
| 2026-08-17 | Patel Sanjiv | S (D) | 48,199 | $20.33 | 567,699 | Form 4 |
| 2026-08-14 | Catinazzo Thomas | S (D) | 17,717 | $19.74 | 140,568 | Form 4 |
| 2026-07-28 | Bergstrom Donald A | S (D) | 2,237 | $18.61 | 407,660 | Form 4 |
| 2026-07-28 | Rahmer Peter | S (D) | 748 | $18.61 | 228,165 | Form 4 |
| 2026-07-28 | Catinazzo Thomas | S (D) | 1,459 | $18.61 | 158,285 | Form 4 |
| 2026-07-07 | Patel Sanjiv | S (D) | 48,199 | $19.58 | 615,898 | Form 4 |
| 2026-07-06 | Catinazzo Thomas | S (D) | 17,717 | $18.69 | 159,744 | Form 4 |
| 2026-07-06 | Bergstrom Donald A | S (D) | 8,660 | $18.71 | 409,897 | Form 4 |
| 2026-06-30 | Patel Sanjiv | A (A) | 3,056 | $6.95 | 664,097 | Form 4 |
| 2026-06-30 | Rahmer Peter | A (A) | 3,056 | $6.95 | 228,913 | Form 4 |
| 2026-06-30 | Rahmer Peter | S (D) | 50,000 | $19.09 | 225,857 | Form 4 |
Transaction codes in this quarter
Get RLAY insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1812364&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · RLAY company page · Relay Therapeutics, Inc. on SEC.gov
Questions
Are insiders buying or selling Relay Therapeutics, Inc. (RLAY)?
In Q3 2026, insiders at Relay Therapeutics, Inc. reported 16 non-derivative transactions on 14 Forms 3, 4 and 5: 0 open-market purchases and 14 sales worth $121.7M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Relay Therapeutics, Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/rlay.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.